Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DANBLOCK
2024-515748-22-01Phase 3Completed
- Sponsor
- Frederiksberg Hospital
- Start
- Aug 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of carvedilol, bisoprolol, metoprolol and nebivolol in myocardial infarction (MI), heart failure (HF), ischemic stroke and 10 more (2 arms), sponsored by Frederiksberg Hospital. Primary endpoint: Composite cardiovascular outcome. Started Aug 2024; status: completed.
02
Drugs
carvedilolbisoprololmetoprololnebivolol
03
Conditions
myocardial infarction (MI)heart failure (HF)ischemic strokecoronary arteriosclerosisAtrial fibrillation (AFib)
Beyond the preview
Go deeper on 2024-515748-22-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515748-22-01.